繁体中文
设为首页
加入收藏
当前位置:药商新药自助发布 >> INCIVEK375毫克(TELAPREVIR,替拉瑞韦锭)

INCIVEK375毫克(TELAPREVIR,替拉瑞韦锭)

ID号:417  发布日期: 2011-11-02    截止日期: 不限  地区:全国 浏览次数:78
部分中文INCIVEKTM处方资料(仅供参考)

INCIVEKTM (telaprevir)膜衣片
美国初始批准:
2011

适应证和用途
INCIVEK是一种丙型肝炎病毒(HCV)NS3/4A蛋白酶抑制剂适用于,与聚乙二醇干扰素α和利巴韦林联用,对有代偿肝病成年患者中基因型1慢性丙型肝炎(CHC)的治疗,包括肝硬变,未治疗过患者或既往曾被基于干扰素治疗治疗过患者,包括既往零反应者(注:治疗期间丙型肝炎病毒负荷达到很小或无减低),部分反应者,和复发者。
(1)INCIVEK必须不用作单药治疗和必须只与聚乙二醇干扰素α和利巴韦林联用。
(2)既往零反应者的高比例(尤其是有肝硬变患者)未达到持续病毒学反应(SVR)和有telaprevir出现对用INCIVEK治疗伴耐药取代。
(3)对既往用包括INCIVEK或其它HCV NS3/4A蛋白酶抑制剂治疗方案已治疗失败患者,INCIVEK疗效尚未确定。

剂量和给药方法
(1)750 mg一天服用3次(间隔7-9小时)与食物(非低脂肪)。
(2)对所有患者INCIVEK必须与聚乙二醇干扰素α和利巴韦林二者给予共12周,接着反应-指导方案或12或36另外周的聚乙二醇干扰素α和利巴韦林依赖于病毒反应和既往反应状态。
(3)对聚乙二醇干扰素α和利巴韦林专门剂量说明,参阅其相应处方资料。

剂型和规格
375 mg片

禁忌证
(1)因为INCIVEK必须与聚乙二醇干扰素α和利巴韦林给药,对聚乙二醇干扰素α和利巴韦林所有禁忌证也应用。
(2)妊娠妇女和男性其女性伴侣妊娠:因为利巴韦林可能引起出生缺陷和胎儿死亡,在妊娠妇女和在男性其女性伴侣妊娠禁忌用telaprevir与聚乙二醇干扰素α和利巴韦林联用。
(3)与以下药物共同给药:
1)对清除高度依赖于CYP3A和升高血浆浓度是伴随严重和/或危及生命事件。
2)强烈诱导CYP3A 可能导致脚底保留和丧失INCIVEK疗效。

警告和注意事项
(1)妊娠:使用利巴韦林和Peg干扰素α:利巴韦林可能引起出生缺陷和胎儿死亡;在女性患者和男性患者的女性伴侣中避免妊娠。初始治疗前患者必须有阴性妊娠检验,采用至少2种有效避孕方法,和每月进行妊娠检验。
(2)严重皮肤反应:严重皮肤反应包括药物皮疹有嗜酸粒细胞增多和全身症状和曾报道Stevens-Johnson综合征。对严重皮肤反应,应立即终止INCIVEK联合治疗的所有化合物。
(3)皮疹:有轻至中度皮疹患者应监视进展。如皮疹进展和成为严重,应终止INCIVEK。
(4)贫血:INCIVEK联合治疗前和期间定期监视血红蛋白。调整利巴韦林剂量;如需要终止INCIVEK。

不良反应
最常见对INCIVEK不良药物反应 (发生率用NCIVEK比对照至少较高5%)是皮疹,瘙痒,贫血,恶心,痔疮,腹泻,肛门直肠不适,味觉障碍,疲乏,呕吐,和肛门瘙痒。

药物相互作用
INCIVEK治疗与其它药物联用共同给药可能改变其它药物的浓度和可能改变telaprevir浓度的其它药物。对药物-药物相互作用潜能治疗期间和前咨询完整处方资料。

特殊人群中使用
(1)肝受损:尚未确定在有Child-Pugh评分大于或等于7(类型B和C)患者中安全性和疗效。
(2)共感染:尚未确定在HCV/HIV和HCV/HBV共感染患者中安全性和疗效。
(3)儿童:尚未确定在儿童患者中安全性和疗效。
(4)实体器官移植:尚未确定在进行实体器官移植患者中安全性和疗效。
(5)可以得到利巴韦林妊娠注册。

Indication
INCIVEK™ (telaprevir) is a prescription medicine used with the medicines peginterferon alfa and ribavirin to treat chronic (lasting a long time) hepatitis C genotype 1 infection in adults with stable liver problems, who have not been treated before or who have failed previous treatment.

It is not known if INCIVEK is safe and effective in children under 18 years of age.

IMPORTANT SAFETY INFORMATION
Who should not take INCIVEK
Do not take INCIVEK if you are pregnant or may become pregnant, or if you are a man with a sexual partner who is pregnant.

Do not take INCIVEK if you are taking certain medicines as there could be serious side effects. If these drugs are taken together, this can cause you to have too much or not enough INCIVEK or your other medicines in your body. It can also cause side effects that can be serious or life-threatening. These medicines include: alfuzosin hydrochloride (Uroxatral®), atorvastatin (Lipitor®, Caduet®), ergot containing medicines such as methylergonovine (Methergine®), lovastatin (Advicor®, Altoprev®, Mevacor®), pimozide (Orap®), rifampin (Rifadin®, Rifamate®, Rifater®), sildenafil citrate (Revatio®) or tadalafil (Adcirca®) for the lung problem pulmonary artery hypertension (PAH), simvastatin (Zocor®, Vytorin®, Simcor®), St. John's wort (Hypericum perforatum), or triazolam (Halcion®).

Talk to your healthcare provider before taking INCIVEK if any of the above applies to you. Your healthcare provider may need to change the amount of medicines you take.

Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. INCIVEK and other medicines can affect each other.

Serious Side Effects
INCIVEK can cause serious side effects, including:
•Birth defects or death of an unborn baby
INCIVEK combined with peginterferon alfa and ribavirin may cause birth defects or death of your unborn baby. If you or your sexual partner is pregnant or plan to become pregnant, do not take these medicines. You or your partner should not become pregnant while taking INCIVEK with peginterferon alfa and ribavirin and for 6 months after treatment is over.
You must have a negative pregnancy test before starting treatment, every month during treatment, and for 6 months after your treatment ends. You must use 2 effective methods of birth control during treatment and for 6 months after all treatment has ended. These 2 forms of birth control should not contain hormones, as these may not work as well during treatment with INCIVEK. Talk to your healthcare provider about the forms of birth control you should use during this time.
Two weeks after stopping INCIVEK, you can use a hormonal form of birth control as one of your two forms of birth control.
If you or your partner becomes pregnant during treatment or within 6 months after stopping these medicines, tell your healthcare provider right away. Contact the Ribavirin Pregnancy Registry right away by calling 1-800-593-2214. The Registry collects information about what happens to mothers and their babies if the mother takes ribavirin while pregnant.
•Skin reactions: Mild skin rashes are common with INCIVEK combination treatment. Sometimes these skin rashes and other skin reactions can become severe and require treatment in a hospital. Call your healthcare provider right away if you develop any skin changes with these symptoms: rash with or without itching, blisters or skin lesions, mouth sores or ulcers, red or inflamed eyes like "pink eye" (conjunctivitis), swelling of your face, or fever.
Your healthcare provider will decide if these changes may be a sign of a serious skin reaction. Your healthcare provider will also decide if you need treatment for your rash or to stop INCIVEK or your other medicines. Never stop taking INCIVEK combination treatment without talking to your healthcare provider first.
•Do not take INCIVEK alone to treat chronic hepatitis C infection. It must be used with peginterferon alfa and ribavirin to treat chronic hepatitis C infection.
•Low red blood cell count (anemia) that can be severe. Tell your healthcare provider if you have any of these symptoms of anemia: dizziness, shortness of breath, tiredness, or weakness.

Your healthcare provider will do blood tests regularly to check your red blood cell count during treatment. If your anemia is severe your healthcare provider may tell you to stop taking INCIVEK. If this happens, do not start taking it again.

What should I tell my healthcare provider before taking INCIVEK?
Tell your healthcare provider if you:
•have certain blood problems such as anemia
•have liver problems other than hepatitis C infection
•have hepatitis B, HIV infection, or any problems with your immune system
•have a history of gout or high uric acid levels in your blood
•have had an organ transplant
•plan to have surgery
•have any other medical condition
•are breastfeeding

How should I take INCIVEK?
Take INCIVEK exactly as your healthcare provider tells you. Take two INCIVEK pills 3 times a day, 7 to 9 hours apart, with food. Eat a meal or snack containing about 20 grams of fat within 30 minutes before you take each dose. Talk to your healthcare provider about examples of food you can eat.

If you miss a dose within 4 hours of when you usually take it, take your dose with food as soon as possible. If you miss a dose and it is more than 4 hours after the time you usually take it, skip that dose only and take the next dose at your normal time. Do not stop taking INCIVEK unless your healthcare provider tells you to. If your healthcare provider tells you to stop, you should not start taking it again, even if the reason for stopping goes away. If you take too much INCIVEK, call your healthcare provider or local Poison Control Center, or go to the nearest emergency room right away.

Common Side Effects of INCIVEK Combination Treatment
The most common side effects include itching, nausea, diarrhea, vomiting, anal or rectal problems (including hemorrhoids, discomfort or burning around or near the anus, itching around or near the anus), taste changes, and tiredness. Tell your healthcare provider about any side effect that bothers you or doesn’t go away.

These are not all the possible side effects of INCIVEK. For more information, ask your healthcare provider or pharmacist.

---------------------------------------------------------------
原产地英文商品名:
INCIVEK 375MG/CAPLET 168CAPLETS/BOTTLE
原产地英文药品名:
TELAPREVIR
中文参考商品译名:
INCIVEK 375毫克/锭 168锭/瓶
中文参考药品译名:
替拉瑞韦
生产厂家中文参考译名:
VERTEX PHARMS
生产厂家英文名:
VERTEX PHARMS
---------------------------------------------------------------

附件:





联系方式
联系人:admin
电 话:
地 址:
E-mail:
Q Q:
发布人信息
发布人:admin
目前身份:
最后登录:
E-mail:
查看用户发布的所有信息 >>

本类最新信息

· Ibrance(Palbociclib)帕博...
· 晚期基底细胞癌重磅新药ODOM...
· BFLUID Injection(Thiamine...
· MIXID L Injection(18种氨基...
· Uralyt(Sodium citrate tri...
· DELTYBA(Delamanid Tablets...
· Vonoprazan,TAK-438(Vonopr...
· LUNABELL tablets(Ethinyles...
· Riona Tab(Ferric Citrate H...
· 重量级丙肝新药Harvoni(sofo...

本类推荐信息

· Ibrance(Palbociclib)帕博...
· 晚期基底细胞癌重磅新药ODOM...
· BFLUID Injection(Thiamine...
· MIXID L Injection(18种氨基...
· Uralyt(Sodium citrate tri...
· DELTYBA(Delamanid Tablets...
· Vonoprazan,TAK-438(Vonopr...
· LUNABELL tablets(Ethinyles...
· Riona Tab(Ferric Citrate H...
· 重量级丙肝新药Harvoni(sofo...

相关信息

INCIVEK(Telaprevir 375mg;片)